in

New Monoclonal Antibody Class Shows Promise for Migraine

Source link : https://www.newshealth.biz/health-news/new-monoclonal-antibody-class-shows-promise-for-migraine/

A potential first-in-class therapy for migraine prevention has shown promise in a phase 2a proof-of-concept study, with a single infusion reducing migraine frequency over 4 weeks. The drug Lu AG09222 from Lundbeck is an investigational monoclonal antibody that targets a pathway in migraine that is distinct from pathways targeted by the calcitonin gene-related peptide (CGRP) […]

Author : News Health

Publish date : 2024-09-06 12:37:57

Copyright for syndicated content belongs to the linked Source.

Michèle Alliot-Marie condamnée à 6 mois de prison avec sursis pour prise illégale d’intérêts

Japan vs. USA In A high-stakes rugby clash In The Pacific Nations Cup – FloRugby